Antioxidant Nanoparticle Shows Promise in Lowering Oxidative Stress in Parkinson’s
Encapsulating the antioxidant small molecule ellagic acid into a nanoparticle that also has some antioxidant properties may be a…
Articles by Inês Martins, PhD
FDA Approves Ongentys as Levodopa Add-on for ‘Off’ Periods
The U.S. Food and Drug Administration (FDA) has approved Ongentys (opicapone) as an oral, add-on daily treatment for Parkinson’s…
Prasinezumab Fails to Slow Symptom Worsening in Parkinson’s, But Shows Other Signs of Effectiveness, Trial Finds
Prasinezumab (PRX002/RG7935), an antibody designed to eliminate the toxic clumps of alpha-synuclein in Parkinson’s disease patients,…
Immune Cells in Blood May Help with Diagnosis Years Before Motor Onset
Immune cells targeting the alpha-synuclein protein are common in Parkinson’s patients, and new research shows that these cells can be present…
Clinical Model Predicts Risk of Levodopa-induced Dyskinesia in Parkinson’s
Some clinical features of Parkinson’s disease patients — such as age at disease onset, disease duration, initial motor symptom,…
Gene Behavior in Brain Hemispheres May Explain Asymmetry of Parkinson’s Symptoms
Differences in gene expression between the left and right hemispheres of the brain may explain why Parkinson’s…
2 Blood Biomarkers of Parkinson’s Seen in Multi-step Protein Analysis
Levels of two mitochondrial-related proteins, clusterin and VPS35, may accurately diagnose Parkinson’s disease using a single blood drop,…
Parkinson’s Symptoms May Help to Judge Ability to Do Daily Tasks
The clinical symptoms experienced by people with Parkinson’s disease, like dyskinesia or postural instability, may help to distinguish…
GB Sciences’ Cannabinoids Entering Final Preclinical Stage to Study Mechanisms of Action
The National Research Council (NRC) of Canada will conduct a final phase of preclinical testing of GB Sciences‘…
Blood Pressure Medicine Dynacirc Falls Short in Phase 3 Trial for Early Parkinson’s
Long-term use of blood pressure medication Dynacirc (isradipine) does not slow disease progression in people with early Parkinson’s…